Table 6.
Pre-formed nanoparticles modified with histidines and imidazoles.
| Carrier | Nucleic Acid | In Vitro /In Vivo |
Comment | Reference |
|---|---|---|---|---|
| Fusogenic H5WYG peptide conjugated to virus-like particles | siRNA | Y/N | About seventy-five “H5WYG” peptides per particle. Without fusogenic peptide, the particles containing siRNA were significantly less effective targeting cyclins in Hep3B cells | [22] |
| Mesoporous silica nanoparticles with L-histidine (MSN-His 1) | pDNA | Y/Y | Improved pDNA transfection efficiency both in vitro and in Achilles tendons in vivo compared to unmodified MS | [98] |
| Imidazole linked to dendritic mesoporous silica nanoparticle | pDNA/Doxoru-bicin | Y/Y | Carrier exhibited high drug loading capacity, pH-sensitive targeting and drug release; marked tumor inhibition with doxorubicin and shSurvivin in vivo | [99] |
| Imidazole framework film covering MSN | siRNA/Doxoru-bicin | Y/N | Ultrathin zinc-imidazole film (or ZIF-8) on MSN adsorbed siRNAs with high efficiency and released siRNA and small drugs readily inside the cells | [100] |
1 MSN-His, mesoporous silica nanoparticles modified by histidines; ZIF-8, zeolithic imidazole framework.